A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...

Fortunately, the S&P 500 recovered to new all-time highs by August 2020 and is now up about 150% from its COVID lows.

Observational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three ...

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...

Commonwealth Equity Services LLC trimmed its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 7.2% in the ...

For example, patients who stop fingolimod (Gilenya) or natalizumab (Tysabri) treatment are at risk of developing rebound disease activity. Two randomized clinical trials -- DISCOMS and DOT-MS ...

Although one patient treated with Ocrevus has reportedly developed PML, Roche blamed this on previous treatment with Tysabri. And while Biogen’s Tecfidera (dimethyl fumarate) pill is also ...